SCH 417690-- VICRIVIROC
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $238,523 | 49 | 0 |
| 2019 | $1.2M | 130 | 0 |
| 2018 | $540,627 | 72 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.0M | 250 | 100.0% |
| Consulting Fee | $675.00 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in participants with advanced,metastatic microsatellite stable MSS colorectal cancer CRC | Merck Sharp & Dohme Corporation | $1.8M | 0 |
| A Phase II study to evaluate the safety and efficacy of Vicriviroc (MK-7690) in combination with Pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC) | Merck Sharp & Dohme Corporation | $238,277 | 0 |
Top Doctors Receiving Payments for SCH 417690-- VICRIVIROC
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Diego, CA | $2.0M | 250 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $675.00 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.0M
- Total Doctors 1
- Transactions 251
About SCH 417690-- VICRIVIROC
SCH 417690-- VICRIVIROC is a drug associated with $2.0M in payments to 1 healthcare providers, recorded across 251 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2020. In 2020, $238,523 was paid across 49 transactions to 0 doctors.
The most common payment nature for SCH 417690-- VICRIVIROC is "Unspecified" ($2.0M, 100.0% of total).
SCH 417690-- VICRIVIROC is associated with 2 research studies, including "A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in participants with advanced,metastatic microsatellite stable MSS colorectal cancer CRC" ($1.8M).